Roquefort Therapeutics PLC (LSE:ROQ, OTCQB:ROQAF) chief executive Ajan Reginald joined Proactive's Stephen Gunnion with news of the company's first licensing deal, which will see it working with diagnostics firm Randox.
Reginald told Proactive that the deal, worth more than £5mln, is one of a number of transactions that are in the pipeline as it develops its cancer therapies.